Effects of low-dose propofol administration on central respiratory drive, gas exchanges and respiratory pattern

The effects of sedative-hypnotic doses of propofol on respiratory drive and pattern have not yet been extensively described. Repeated small boluses of propofol (0.6-0.3 mg.kg-1) were administered to ten ASA I patients undergoing carpal tunnel release using regional anaesthesia. Airway pressure, capnography and pneumotachography were continuously recorded. With respect to basal values, no significant variations of respiratory rate, minute volume, tidal volume, inspiratory and expiratory time, total expiratory cycle, Ti/Ttot, TV/Ti, P0.1, EtCO2 and blood gas analysis were observed. Low doses of propofol, to maintain conscious sedation of light sleep, have not been shown to cause respiratory depression.     

überlebensverbesserung eines unizentrischen Gesamtkollektivs aus 20 Jahren

PURPOSE: The development of overall survival of a DOSAK (German-Austrian-Swiss Cooperative Group on tumours of the maxillofacial region) clinic's overall population comprising a time period of more than 20 years (1983-2004) should be assessed. At a cutoff date (January 1st, 1997), a change from a primarily surgically based to a consequent multi-modality treatment regimen was implemented. The periods of time before and after that change should be compared. METHODS AND PATIENTS: The data of the DOSAK registry entries on 1038 patients suffering from primary untreated oral and oropharyngeal carcinomas were updated with respect to follow-up and mortality data to achieve a 100% quality of follow-up. The end point (death) was reached in 67% of the overall population. Statistical analysis was carried out by the Trium Analysis Online corporation, Munich. RESULTS: The portion of female and older tumor patients increased, more than half of all tumor patients were clearly in stage IV of the disease at first referral. The portion of patients operated on persisted approximately (80%), the portion of additional treatment modalities could be increased considerably. The fact of a bony infiltration by the tumor and the operability remained highly significantly relevant for survival in multivariate analysis, despite of multi-modality treatment. The survival rate of the patients remained significantly dependent on the clinical stage of the disease in multivariate analysis but could be improved by 10% in the clinical stages II and III and in the patients who could not be operated on. All in all, the cutoff date was statistically relevant for survival in multivariate analysis, i.[Symbol: see text]e. the change in the treatment regimen had a verifiable positive effect on the survival of a unicentric overall population. CONCLUSION: Survival improvement in an overall population via change in treatment strategy is possible in relatively short time; the clinical stages II and III and the non-operable patients have the greatest benefit from a multi-modality treatment.     

New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice

The introduction of second-generation microbubble ultrasound contrast agents and the development of contrast specific ultrasound techniques have improved the ability of contrast enhanced ultrasound in detecting and characterising liver lesions, offering new perspectives for its exploitation in clinical hepatology. Indeed, several studies have demonstrated a high diagnostic accuracy in focal lesion characterisation (85-96%) in patients either with or without underlying chronic liver disease. This review article describes the basic principles of contrast enhanced ultrasound, defines the different vascular features of benign and malignant liver lesions, and assesses its clinical impact in different clinical scenarios, according to the guidelines of the European Federation of Societies for Ultrasound in Medicine and Biology, contrast enhanced ultrasound enables the characterisation of focal liver lesions, regardless of the presence or absence of underlying chronic liver disease. Contrast enhanced ultrasound is also useful in staging and follow-up of cancer patients and in monitoring local ablative treatment. Contrast enhanced ultrasound is expected to be considerably increased and replace many computed tomography and magnetic resonance imaging examinations in near future, according to the European Federation of Societies for Ultrasound in Medicine and Biology guidelines. Therefore, it is necessary to take measures in order to meet the demand for an increasing number of these procedures.     

医用透明质酸钠预防腹部手术后腹腔粘连的临床观察

目的　观察医用透明质酸钠对预防腹部手术后腹腔粘连的作用。方法 136 0例腹部手术患者 ,关腹前于腹膜及腹腔创面涂抹医用透明质酸钠 (sodiumhyaluronate)凝胶剂 3～ 15ml,随访期间 ,2 3例患者获 2次手术探察的机会 ,观察腹腔粘连程度 ,并与同期未用透明质酸钠凝胶剂的 2 6例 2次手术患者作对比分析。结果观察组 :腹腔粘连Ⅰ级 11例 ,Ⅱ级 9例 ,Ⅲ级 3例 ,Ⅳ级 0例 ;对照组 :Ⅰ级 1例 ,Ⅱ级 5例 ,Ⅲ级 17例 ,Ⅳ级 3例。两组轻度粘连分别为 87%和 2 3% ;两组重度粘连分别为 13%和 77%。两组患者手术后腹腔内粘连情况比较 ,差异有显著意义 (P <0 0 1)。结论透明质酸钠凝胶对腹部手术后预防腹腔粘连具有明显效果。     

凝固酶阴性葡萄球菌检测在慢性前列腺炎中的意义

目的　研究慢性前列腺炎与凝固酶阴性葡萄球菌 (CNS)的关系 ,探讨前列腺液中CNS检测的临床意义。　方法　对 4 2 8例慢性前列腺炎患者采用Meares Stamey四段取样法作前列腺液细菌培养和药敏试验。患者年龄 18～ 4 6岁 ,平均 31岁。病程 3～ 32个月 ,平均 6个月。慢性前列腺炎症状指数 (NIH CPSI)平均 2 3.2分。　结果　 4 2 8例均行细菌培养 ,其中 2 4 8例 (5 7.94 % )分离出细菌。革兰阳性菌 195例 (78.6 3% ) ,其中葡萄球菌 16 0例 (6 4 .5 2 % ,16 0 / 2 4 8) ,CNS 89例 (35 .89% ,89/ 2 4 8) ;CNS中以表皮葡萄球菌为主者 81例 (32 .6 6 % ) ,其次为腐生葡萄球菌 3例和溶血性葡萄球菌 2例 ;NIH CPSI积分与细菌培养结果无明显相关。CNS对常用抗菌药物 (β 内酰胺类、喹诺酮类、氨基糖苷类 )耐药率较高 (5 1.9%～ 10 0 % )。　结论　CNS为慢性前列腺炎的主要致病菌 ,应引起高度重视 ;适时监测前列腺液病原菌及药敏试验对临床诊断和治疗慢性前列腺炎具有重要意义。     

肝移植大鼠肝内一氧化氮合酶的表达

目的 :探讨移植肝一氧化氮合酶的表达与急性排斥反应间关系及其细胞定位。方法 :应用近交系 BN至 Lew大鼠原位肝移植急性排斥反应及同基因 ( Lew- Lew)肝移植动物模型 ,用免疫组化法检测移植肝组织中诱导型一氧化氮合酶 ( i NOS)的表达。同时观察 i NOS抑制剂氨基胍和免疫抑制剂 FK5 0 6对肝移植术后急性排斥反应的影响。结果 :在急性排斥组 i NOS表达强阳性 ,与氨基胍组、FK5 0 6组及同基因对照组比较差异显著。结论 :在大鼠原位肝移植发生急性排斥反应时 i N-OS增高程度与排斥反应的强度有明显关系。氨基胍、FK5 0 6可以抑制 i NOS的表达。抑制 i NOS的表达可明显减轻移植肝组织的急性排斥反应     

可逆性胆碱酯酶抑制剂的研究:2-氧化-1,3,2-二氧磷杂环己烷类化合物的合成

本文报道2-氧化-1,3,2-二氧磷杂环己烷类衍生物的合成,希望寻找效果较好的可逆性胆碱酯酶抑制剂。初步药理实验证明,所合成的大部分化合物具有一定的抑制乙酰胆碱酯酶的作用,且毒性较低。通过对中间体Ⅱ进行质谱分析,发现该类化合物中大部分存在M-57碎片离子峰,利用高分辨质谱和亚稳离子测定,确定了该碎片离子的生成过程。     

围术期维持活体部分移植小肠血供的措施

目的：探讨围术期维持移植小肠血液灌注的方法，方法：男，18岁，短肠综合征患者，全麻下接受其父亲供给末段回肠150cm，行活体部分小肠移植，围主期维持出入量平衡，中度等容血液稀释，选用扩血管药，防止血管痉挛，以及抗凝治疗，结果：术的31d脱离肠外营养，至今已术后34mo，未发生移植小肠明显缺血性改变。结论：采用上述方法匀是维持围术期移植小肠血供的重要措施。     

钚促排药物的设计与合成

利用仿生化学的原理，本文设计并合成了两个儿茶酚胺类和两个羟基吡啶酮类八配位的螯合剂，初步动物试验表明，具有较强的钚促排能力。